MX2010008103A - Metodo para optimizar el tratamiento de enfermedades proliferativas mediadas por el receptor de cinasa de tirosina kit con imatinib. - Google Patents

Metodo para optimizar el tratamiento de enfermedades proliferativas mediadas por el receptor de cinasa de tirosina kit con imatinib.

Info

Publication number
MX2010008103A
MX2010008103A MX2010008103A MX2010008103A MX2010008103A MX 2010008103 A MX2010008103 A MX 2010008103A MX 2010008103 A MX2010008103 A MX 2010008103A MX 2010008103 A MX2010008103 A MX 2010008103A MX 2010008103 A MX2010008103 A MX 2010008103A
Authority
MX
Mexico
Prior art keywords
proliferative diseases
typosine
imatinib
optimize
treatment
Prior art date
Application number
MX2010008103A
Other languages
English (en)
Spanish (es)
Inventor
Yanfeng Wang
Elisabeth Wehrle
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40435094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010008103(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010008103A publication Critical patent/MX2010008103A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2010008103A 2008-01-23 2009-01-21 Metodo para optimizar el tratamiento de enfermedades proliferativas mediadas por el receptor de cinasa de tirosina kit con imatinib. MX2010008103A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2294508P 2008-01-23 2008-01-23
PCT/US2009/031510 WO2009094360A1 (en) 2008-01-23 2009-01-21 Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib

Publications (1)

Publication Number Publication Date
MX2010008103A true MX2010008103A (es) 2010-08-23

Family

ID=40435094

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008103A MX2010008103A (es) 2008-01-23 2009-01-21 Metodo para optimizar el tratamiento de enfermedades proliferativas mediadas por el receptor de cinasa de tirosina kit con imatinib.

Country Status (14)

Country Link
US (3) US20100298338A1 (enExample)
EP (1) EP2237783B1 (enExample)
JP (2) JP5936821B2 (enExample)
KR (1) KR101579993B1 (enExample)
CN (1) CN101951910B (enExample)
AU (1) AU2009206566A1 (enExample)
BR (1) BRPI0906504A2 (enExample)
CA (1) CA2712087A1 (enExample)
ES (1) ES2526537T3 (enExample)
MX (1) MX2010008103A (enExample)
PL (1) PL2237783T3 (enExample)
PT (1) PT2237783E (enExample)
RU (1) RU2537223C2 (enExample)
WO (1) WO2009094360A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2753391C1 (ru) * 2020-09-29 2021-08-13 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ оптимизации лечения стромальных опухолей желудочно-кишечного тракта

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
GB0127922D0 (en) * 2001-11-21 2002-01-16 Novartis Ag Organic compounds
SI1686997T1 (sl) * 2003-11-18 2009-08-31 Novartis Ag Inhibitorji mutantne oblike KIT
US7329495B2 (en) * 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
MX2009003082A (es) * 2006-09-22 2009-04-01 Novartis Ag Metodo para optimizar el tratamiento de leucemia positiva para filadelfia, con inhibidores de cinasa de tirosina abl.
US8119841B2 (en) 2006-11-07 2012-02-21 Novartis Ag Crystalline forms of aliskiren hemifumarate

Also Published As

Publication number Publication date
RU2537223C2 (ru) 2014-12-27
CA2712087A1 (en) 2009-07-30
US20100298338A1 (en) 2010-11-25
ES2526537T3 (es) 2015-01-13
PL2237783T3 (pl) 2015-04-30
EP2237783A1 (en) 2010-10-13
KR20100105778A (ko) 2010-09-29
US20160045501A1 (en) 2016-02-18
US20170035757A1 (en) 2017-02-09
PT2237783E (pt) 2014-12-23
US9763944B2 (en) 2017-09-19
BRPI0906504A2 (pt) 2015-07-14
JP2011510086A (ja) 2011-03-31
RU2010134916A (ru) 2012-02-27
CN101951910B (zh) 2013-07-17
JP5881671B2 (ja) 2016-03-09
JP2014094946A (ja) 2014-05-22
JP5936821B2 (ja) 2016-06-22
KR101579993B1 (ko) 2015-12-23
WO2009094360A1 (en) 2009-07-30
AU2009206566A1 (en) 2009-07-30
CN101951910A (zh) 2011-01-19
EP2237783B1 (en) 2014-11-19

Similar Documents

Publication Publication Date Title
EA201171367A1 (ru) Винилиндазолильные соединения
DOP2010000369A (es) Inmunoglobulinas con dominio variable dual y usos de la misma
CR20120266A (es) Inmunoglobinas con dominio variable dual y usos de las mismas
ECSP088279A (es) Ciclopropil aminas como moduladores del receptor de histamina h3
DOP2010000368A (es) Inmunoglobulinas con dominio variable dual y usos de la misma
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
TN2009000529A1 (en) Methods and compositions for treating allergic diseases
DOP2011000333A (es) Inmunoglobulina con dominio variable dual y usos de la mismas
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
CR20120267A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2011011670A (es) Inmunoglobulinas de dominio variable dual y usos de las mismas.
TW200736275A (en) Methods and compositions for treating allergic diseases
CR20120154A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2569434A4 (en) COMPOSITIONS AND METHODS OF TREATING LEUKEMIA
MX2012001974A (es) Compuestos de biarilo y metodos de uso de los mismos.
UY31478A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
PH12015501806B1 (en) Novel benzopyran kinase modulators
IN2012DN02471A (enExample)
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
DK3135672T3 (da) Sammensætninger og fremgangsmåder til behandling af alkoholforbrugslidelser, smerter og andre sygdomme
MY150600A (en) Use of opioid antagonists for treating urinary retention
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
UA107346C2 (en) Use of nifuratel to treat infections caused by atopobium species
MX2010008994A (es) Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.

Legal Events

Date Code Title Description
FG Grant or registration